Table 9. Challenges and recommendations for National TB Programmes.
Category | Challenges | Proposed remedies |
---|---|---|
End TB Milestones/Targets on TB
incidence and mortality |
Presented globally as percentage reductions
compared with 2015 |
Change percentage reductions into absolute
“national” numbers against which to measure progress and present them for all levels of the health system |
Optimize prompt and accurate
diagnosis of TB |
Inefficient use of smear microscopy and
Xpert MTB/RIF |
Develop algorithms for best use of smear
microscopy/Xpert MTB/RIF; monitor numbers being screened, tests done, and results; monitor operational capacity of MTB/RIF instruments; keep abreast of new diagnostic molecular technology |
Provide rapid, complete, and
effective treatment to all those diagnosed with TB |
Poor linkage of diagnosis and treatment;
wrong denominator for measuring treatment outcomes; high rates of “not evaluated” |
Monitor and improve linkage to care; use
diagnosed TB patients as the denominator for treatment outcomes; obtain treatment outcomes for transfer-out patients |
Implement and monitor
effective infection control practices for MTB |
Poor infection control practices and
monitoring of TB infection control |
Implement and monitor World Health
Organization-recommended guidelines; monitor rates of TB in health workers |
Diagnose and treat drug-resistant TB | Poor linkage to care; continued use of
inefficient CDST systems at national laboratories; long duration of therapy |
Monitor and improve linkage to care; prioritize
and plan for more efficient use of Xpert MTB/RIF; aim for short 9- to 12-month multidrug-resistant TB treatment; keep abreast of new diagnostic molecular technology |
Diagnose and treat HIV infection and
diabetes mellitus |
HIV and diabetes increase TB mortality;
suboptimal uptake of HIV testing, ART, and CPT; limited screening of TB patients for diabetes |
Aim for 100% uptake of HIV interventions; scale
up screening of TB patients for diabetes and provide optimal diabetes care during anti-TB treatment |
ACF and treatment of LTBI | Poor programmatic implementation of ACF
and treatment of LTBI |
Design and implement strategies with particular
focus on people living with HIV and household contacts |
Engage with private-for-profit sector | Poor implementation of the PPM strategy | Focus on ways to improve the PPM strategy,
especially in Asia |
Empower and strengthen central
units of TB Programs |
Weak central units | More focus on data-driven supportive
supervision, operational research, and sustained financing |
ACF, active case finding; ART, antiretroviral therapy; CDST, culture and drug susceptibility testing; CPT, cotrimoxazole preventive therapy; LTBI, latent tuberculosis infection; MTB, Mycobacterium tuberculosis; PPM, public-private mix; TB, tuberculosis.